My Treatment Approach Enhancing Treatment for Relapsed/Refractory Multiple Myeloma (RRMM): Converting Evidence to Effective Clinical Care - Episode 5
Important Patient and Clinical Considerations When Choosing Therapy in RRMM Following CAR T Therapy
Panelists discuss how selinexor offers convenient oral administration, bispecific antibodies provide high response rates but may present toxicity risks, and cytotoxic chemotherapy is effective for aggressive disease but carries significant adverse effects and risks.
Physician Summary: Advantages and Disadvantages of Available Treatment Options
Selinexor:
- Advantages:
- Oral administration allows for easier access and reduces the need for frequent clinic visits.
- Convenient for patients who may prefer oral therapy over intravenous options.
- Disadvantages:
- Can have adverse effects like nausea and fatigue.
- May require dose adjustments based on tolerance.
Bispecific Antibodies:
- Advantages:
- High response rates in patients, offering effective disease control.
- Available as off-the-shelf therapies, providing rapid access.
- Disadvantages:
- Potential for toxicity, including cytokine release syndrome and neurotoxicity.
- Access limitations due to the need for specialized administration and possible cost issues.
- Infection risk due to immune modulation.
Cytotoxic Chemotherapy:
- Advantages:
- Effective for aggressive disease with quick action in cytoreduction.
- Broad applicability in various clinical settings.
- Disadvantages:
- Associated with myelosuppression, renal dysfunction, and the potential for hospitalization due to adverse effects.
- T-cell suppression, which can impair responses to subsequent immunotherapies.
Key Takeaway: Each treatment has its own benefit-risk profile—selinexor offers convenience, bispecific antibodies deliver high response rates, and cytotoxic chemotherapy can be effective in aggressive disease, though each carries specific challenges in terms of toxicity and patient burden.
Related Content:
